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The development of the typical comorbidities of aging which currently affects people living with HIV/AIDS (PLWHA) can be
partially ascribed to the persistent immune activation and chronic inflammation characterizing these individuals. The aim of this
study was to analyze the effect exerted by combined antiretroviral therapy (cART) administration on plasma levels of HMGB1
(high mobility group box protein-1), AGEs (advanced glycation end products), their soluble receptor sRAGE, cytokines, C-
reactive protein (CRP), and some metabolic markers in asymptomatic PLWHA. Analyses were performed longitudinally in 30
PLWHA, before and about 6–12 months after cART initiation. We observed that lower levels of AGEs in post-cART group were
accompanied by an increase of CRP and triglyceride levels already in the earlymonths of therapy. Because of the current ever-earlier
recommendations to start cART and its prolonged use, these and other markers should be investigated in order to monitor and
postpone the appearance of non-AIDS comorbidities in PLWHA.
1. Introduction
Although the HIV epidemics affect more than 36 million
individuals worldwide, with a global prevalence of almost
1% [1], life expectancy of people living with HIV/AIDS
(PLWHA) is very similar to that of the general uninfected
population, which makes the clinical approach to the infec-
tion similar to that of other chronic diseases that characterize
aging [1–3]. This improvement is due to the combination
of several actions and advances in this area, especially the
guaranteed access to potent and combined antiretroviral
therapy (cART) to the majority of the population [1, 2, 4].
However, the great challenge today is to delay the onset
and severity of non-AIDS-defining comorbidities, which
appear much earlier in HIV-infected individuals [5] and
include cardiovascular diseases, diabetes mellitus, kidney,
liver, and bone alterations, and neoplasia [4–8]. The onset
and severity of these comorbidities are strictly dependent
on the intense immune activation and chronic inflammation
affecting PLWHA, regardless of cART administration, which
can only partly reduce these conditions and the derived
products [3, 7]. Furthermore, the toxicity and adverse effects
of cART can also foster the development of such diseases
[7, 9], mainly dyslipidemia.
Advanced glycation end products (AGEs) are a con-
sequence of oxidative stress which occur during normal
physiological conditions such as aging. However, if they are
not excreted in the urine or their formation is exacerbated
as in the case of diabetes hyperglycemia and other diseases,
they accumulate in the vascular tissue, causing harmful
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effects [10, 11]. Furthermore, their binding to their receptors
(RAGE) promotes the activation of proinflammatory and
procoagulant cellular pathways, thus increasing the produc-
tion of adhesion molecules, cytokines such as IL-6 and TNF-
𝛼, and the generation of nitric oxide (NO).Thesemechanisms
can influence the course of HIV infection and contribute to
a number of serious pathological conditions, including the
development of atherosclerosis, diabetesmellitus, osteoporo-
sis, neoplasia, neurological disorders, among others [11–17].
It has also been observed that an alternative mRNA
splicing which removes RAGE transmembrane domain [18,
19] results in the production of a soluble RAGE (sRAGE)
[20]. sRAGE competes with the transmembrane receptor
sequestering its ligands and preventing the activation of
proinflammatory pathways [19]. Therefore, changed sRAGE
levels have been associated with increased cardiovascular
risk [14, 21], hypercholesterolemia [22], and high blood
pressure [23], as well as diabetesmellitus [10], and new drugs
prompting RAGEblocking and/or sRAGE increase have been
proposed for future therapies [18].
High mobility group box protein-1 (HMGB1) is another
key factor in promoting inflammation. It can be actively
secreted following different stimuli, such as cytokines, endo-
toxins, and pathogen-associatedmolecular patterns (PAMPs)
[24], or, passively, by necrotic cells [25], common conditions
observed in HIV-individuals. In the extracellular environ-
ment, HMGB1 activates various pattern-recognition recep-
tors (PRRs), such as RAGE and toll-like receptors (TLR) [26–
28], and acts as a proinflammatory cytokine [25] and alarmin,
stimulating both innate and adaptive immune system to
prevent damage and promoting regeneration and repair [29].
In humans, its high systemic levels are related to several acute
and chronic inflammatory conditions, including pancreatitis,
diabetes mellitus, rheumatologic and autoimmune diseases,
and cancer [17, 28, 30–32].
Few studies have investigated the role of these markers in
HIV infection and how their expression is altered following
cART initiation. Considering the need for better understand-
ing of inflammatory mechanisms and cellular activation in
this patients, as well as their influence on the “premature
aging” phenomenon, the aim of this study was to compare
the levels of HMGB1, AGEs, sRAGE, and some inflammatory
biomarkers in the plasma of asymptomatic PLWHA before
cART and approximately six months to one year after its
introduction.
2. Materials and Methods
2.1. Study Design. This is a longitudinal study involving
30 HIV-infected subjects, attended at the Specialist Out-
patient Service for Infectious Diseases “Domingos Alves
Meira” (SAEI-DM), at the BotucatuMedical School Complex
(FMB)-UNESP, in Sa˜o Paulo state, Brazil. This service covers
about 600 people from Botucatu city and surrounding area
and, for this study, 150 people (those cART-na¨ıve) were
interviewed, with only 30 of them being included after
applying the exclusion criteria.The collection of data and bio-
logical samples was carried out in two stages, before therapy
initiation (M0) and approximately six to twelve months after
this intervention (M1), according to the patient regular return
in the service.This research project was approved by the local
Research Ethics Committee and was conducted between the
years 2012 and 2015.
2.2. Inclusion and Exclusion Criteria. The inclusion criteria
were age between 20 and 50 years, no previous cART
administration, and signing an informed consent form.
Patients excluded were those with any of the follow-
ing conditions: use of vitamin supplements, cancer history
(current or previous), anorexia, morbid obesity, diabetes
mellitus, cardiovascular, genetic, or autoimmune diseases,
organ transplants, pregnancy at any stage or breastfeeding,
coinfections such as tuberculosis, chronic viral hepatitis,
cerebral or disseminated toxoplasmosis, and use of illicit
drugs and alcohol. For the following criteria, exclusion
occurred when patients concomitantly reported two of them
ormore: regular performance of intense physical exercise; use
of antibiotics, anxiolytics, or antidepressants; active smoking.
People with only one of these conditions were included
because the statistical analysis was conducted in adjusted
models for these variables.
2.3. Sociodemographic and Clinical Data. Sociodemographic
and clinical data were collected by interviews and from the
patients’ medical records.Most of the participants weremales
(60.0%) aged approximately 34 years (±8.2), heterosexual
(66.6%), and single (36.6%). The mean duration of HIV
infection, considering its diagnosis, was 2.2 years (±3.2), and
70% of subjects showed a CD4+ T cells count lower than 500
cells/mm3 in the first collection, with nadir of 335.7 ± 211.3
cells/mm3.
Furthermore, 30.0%were active smokers, 23.3%practiced
intense physical activity, and 6.6% were taking anxiolytics
and/or antidepressants.
Results from the following tests were collected from the
medical records: plasma HIV viral load (VL), CD4+ T cells
count, glucose, triglycerides, total cholesterol, and C-reactive
protein (CRP). Adherence to cART was considered, at first,
based on the reports of patients and subsequently verified
with the records of medicine withdrawal, at the pharmacy
service.
2.4. Performance of Laboratory Tests. Twelve milliliters of
bloodwere collected into anEDTAcontaining tube fromeach
patient included in the study. The sample was maintained
in a cooled and dark environment for 2-3 hours and then
centrifuged at 1,500 rpm (Centrifuge 5702R Eppendorf ) for
10 minutes at 10∘C. Six plasma aliquots per individual were
stored at −80∘C until the tests were performed.
2.4.1. Measurement of Plasma HMGB1. A sandwich-type
immunoenzymatic assay (ELISA) was performed, using
100 𝜇L of diluted sample (1 : 10) and following the manu-
facturer’s specifications from commercial kit (MyBioSource,
item MBS2707497). Plasma HMGB1 concentration was
determined by spectrophotometry, at 450 nm. Results were
expressed as pg/mL using the optical density (OD) of the
curves and samples for this calculation.
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Table 1: Clinical data of 30 PLWHA before and after cART initiation.
Variable M0 (MEAN ± SD) M1 (MEAN ± SD) 𝑝 value
CD4+ T count (cells/mm3) 454.69 ± 136.38 625.07 ± 276.94 <0.0001
HIV VL (RNA copies/mm3) 126,550.8 ± 9,756.2 30,813.3 ± 27,463.9 0.019
Undetectable HIV VL — 80.0% —
cART regimen – NRTI + NNRTI — 83.3% —
cART regimen – NRTI + PI/r — 16.7% —
PLWHA: people living with HIV/AIDS; cART: combined antiretroviral therapy; VL: viral load; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI:
nonnucleoside reverse transcriptase inhibitor; PI/r: protease inhibitors reinforced with ritonavir; M0: before cART initiation; M1: after cART initiation.
Statistical tests: gamma distribution for CD4+ T cell count and Poisson to HIV VL.
2.4.2. Measurement of Plasma AGEs. A commercial ELISA
kit (Cell Biolabs Inc., item STA-317) was used following the
protocol provided by the manufacturer, with 100𝜇L of pure
sample. Absorbance was read by a spectrophotometer at a
wavelength of 450 nm and, based on the OD of the sample
and curve, AGEs levels were calculated in 𝜇g/mL.
2.4.3. Measurement of sRAGE. Using 100 𝜇L of pure samples,
the sandwich ELISA protocol was developed according to
themanufacturer’s instructions (R&DSystems, itemDRG00).
Reading was performed immediately by a spectrophotometer
at the wavelength of 450 nm. OD of the samples and curve
were calculated and expressed in pg/mL.
2.4.4. Measurement of IL-6, IL-8, and IL-10. Cytokine mea-
surement was performed by flow cytometry (FACSCalibur-
E34297502374) using the CBA (cytometric bead array) kit
of inflammatory cytokines, according to the manufacturer’s
instruction manual (BD-Becton, Dickinson and Company,
item 551811). The fluorescence intensity, from the cytometer,
showed the amount of cytokines present in the sample. With
the samples, standards containing known concentrations of
each cytokine were analyzed together for the drawing of the
curve, reading, and establishment of the respective detection
limits. Results were obtained in pg/mL by the software FCAP
array (BD-Becton, Dickinson and Company).
2.5. Analysis of Results. Continuous variables were expressed
as mean (ME) and standard deviation (SD) and categorical
variables by frequency and percentage (%). We used Poisson
test or gamma distribution for nonparametric variables and
negative binomial or one-way ANOVA with subsequent
Tukey-Kramer post hoc test for those parametric data. We
also performed Pearson correlations among the continuous
clinical variables: AGE, sRAGE, HMGB1, glucose, triglyc-
erides, total cholesterol, CRP, cytokines, and CD4+ T cells.
All calculations were adjusted for age, sex, and tobacco
use, practice of intense physical activity, and use of anxiolytics
and/or antidepressants.
Significant differences were considered when 𝑝 values
were less than or equal to 0.05. All analyses were performed
with help from professionals at the institution’s Research
Support Office, using SAS for Windows, version 9.2.
3. Results
In this study, we observed an increase in the patients’ CD4+
T counts (454.69 ± 136.38 versus 625.07 ± 276.94 cells/mm3,
𝑝 < 0.0001) after cART (Table 1). It is noteworthy that the
average of CD4+ T cells gain was 170.38 cells/mm3 and it was
higher in individuals with a count lower than 500 cells/mm3
(209.71 cells/mm3) at the beginning of the therapy, compared
to those with an initial count above 500 cells/mm3 (109.62
cells/mm3). In Brazil, although the treatment is offered to all
HIV-infected, before December 2013, therapy was initiated
only for symptomatic patients or patients with CD4+ T
counts below 500 cells/mL.
Among the PLWHA studied, 83.3% were under a thera-
peutic regimen consisting of the nonnucleoside reverse tran-
scriptase inhibitors (NNRTI), and 80.0% had undetectable
VL at M1. At the moment of this second collection, the par-
ticipants were asked about adherence to therapy, which was
reported by 86.6% of them.The average of VLmeasurements
in pre-cART was 126,550.8 (±69,756.2) RNA copies/mm3.
At M1, 80.0% of the patients had undetectable VL; in the
remaining 20% patients, VL was 30,813.3 (±27,463.9) RNA
copies/mm3. Viral load differences between M0 and M1
reached statistical significance (𝑝 = 0.019) (Table 1).
Differences in triglyceride serum levels were observed as
well (142.90±53.38 versus 184.90±115.07mg/dL, 𝑝 = 0.001)
comparing M0 andM1. Conversely, no differences in glucose
and total cholesterol were observed at the two moments
(Figure 1).
After cART introduction, AGEs plasma levels (0.64±0.12
versus 0.49 ± 0.10 pg/mL, 𝑝 < 0.001) decreased significantly
(Figure 2). In order to investigate the influence of CD4+ T
cells on this change, patients were divided into two groups
according to their CD4 T counts at M0 (> or < than 500
CD4 cells/mm3, 𝑛 = 11 and 19 individuals, resp.). Results
suggest that AGEs decrease occurred only in individuals with
an initial CD4+ T count below 500 cells/mm3 (𝑝 = 0.049).
There were no differences for sRAGE (𝑝 = 0.175) or HMGB1
(𝑝 = 0.119) as shown in Figure 2.
CRP levels also increased after sixmonths of cART (0.74±
0.41 versus 1.06 ± 0.99mg/dL, 𝑝 = 0.006); however, no
differences in cytokine levels were observed comparing M0
and M1 (Figure 3).
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Figure 1: Mean of blood glucose measurements, total cholesterol, and triglycerides of 30 PLWHA, before and after cART initiation. PLWHA:
people living with HIV/AIDS; cART: combined antiretroviral therapy; M0: before cART initiation; M1: after cART initiation. Statistical tests:
gamma distribution for triglycerides and ANOVA with post hoc Tukey’s tests for the other variables. ∗𝑝 < 0.001.
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Figure 2: Plasma levels of RAGEs, AGEs, and HMGB1 of 30 PLWHA, before and after cART initiation. PLWHA: people living with
HIV/AIDS; cART: combined antiretroviral therapy; AGEs: advanced glycation end products; sRAGE: soluble receptor of AGEs; HMGB1:
highmobility group box protein-1. M0: before cART initiation; M1: after cART initiation. Statistical tests:ANOVAwith post hoc Tukey’s tests.
∗𝑝 < 0.0001.
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Figure 3: Changes in plasma levels of cytokines and CRP of
30 PLWHA, before and after cART initiation. PLWHA: people
living with HIV/AIDS; cART: combined antiretroviral therapy; IL:
interleukin; CRP: C-reactive protein; M0: before cART initiation;
M1: after cART initiation. Statistical tests: gamma distribution. ∗𝑝 <
0.01. Units of measurement: “mg/dL” to CRP and “pg/mL” to
cytokines.
After the Pearson correlation among the studied vari-
ables, we only observed that IL-10 level was positively
correlated with IL-8 and CRP and CD4+ T cell count was
negatively correlated with IL-6 and IL-8.
4. Discussion
The risk of progression to AIDS and death are related to
high viremia and low CD4+ T lymphocyte level [33], which
reinforces the importance of adherence to cART and regular
monitoring of all these parameters in the clinical practice.The
majority of treatment-na¨ıve patients who start cART show a
decrease in VL to undetectable levels (<40 copies/mm3) and
an increase in CD4+ T cell counts after approximately six
months of therapy [1].This trendmirrors the results obtained
in this study as well as the actual tendency in Brazil, as shown
in the last Epidemiological Bulletin, where undetectable VL
is achieved by 78% of the patients after therapy in both 2013
and 2014 [4].
In order to delay the decrease in CD4+ T cells to very
low levels, current recommendations are to begin treatment
as soon as the diagnosis of HIV infection is confirmed,
regardless of CD4+ T counts. Despite this knowledge, 26%
of Brazilians have a very late diagnosis, when their CD4+
T count is below 200 cells/mm3 and, as a result, they also
begin treatment later [4]. Likewise, in this study, 70% of the
patients showed fewer than 500 cells/mm3 and a nadir of
335.7 cells/mm3 at M0. However, similar to a previous study
performed by our research group [34], the gain of CD4+ T
cells after cART was more evident in patients who had lower
counts at M0.
Despite the benefits of cART in the stabilization of HIV
infection, there is evidence that the therapy is accompanied
by some adverse effects, especially considering its long-term
administration [9, 35]. Although increased oxidative stress
[35] and dyslipidemia [9, 36] are some of the most evident
side effects, in our study, no differences in glucose and total
cholesterol levels were observed after therapeutic interven-
tion.However, we cannot exclude that longer treatment could
provoke these problems, as Pinto Neto et al. [35] observed
that dyslipidemia and glucose disturbances occurred after
three years of cART use. On the other hand, in our study,
patients showed a significant increase in triglyceride levels
already in the first months of treatment, with no influence
of the scheme used, protease inhibitors (PI), or NNRTI
(data not shown). However, other authors reported that
the metabolic imbalance may be associated with different
cART regimens, especially those including some PI [36].
Such changes should be monitored, as they contribute to the
appearance of comorbidities not related to AIDS, such as
cardiovascular disease and diabetesmellitus [8].
Early aging has been associated with and explained by
the persistent immune activation and inflammation shown
by HIV-infected individuals due to residual HIV replication
in lymphoid tissues, the intense microbial translocation that
may occur, themetabolic imbalance, and the instability of the
cytokine profile and of the redox status, among others [7, 37–
39]. It is known that cART reduces inflammation but does
not restore the physiological base level [3, 7]. Referring to
the inflammatory process, cytokines and CRPmeasurements
were studied here before and after cART introduction. Most
of our patients showed undetectable levels of cytokines,
which, in a way, could be justified by the asymptomatic
condition and absence of comorbidities in the studied time.
Furthermore, plasma levels of cytokines, except of TNF-𝛼,
were also extremely low in study by Fahey [40] also with
HIV-infected individuals. Another explanation for these low
values is the choice of technique used to measure them
(CBA), which may have been less sensitive compared to
traditional ELISA.
No significant statistical differences were observed in IL-
6, IL-8, and IL-10 levels production here, although IL-6 has
presented a slightly lower value and the IL-10 levels were
more prevalent after cART initiation. Other authors reported
a decrease in IL-6 synthesis after therapy introduction,
considering a longer intervention, of one to two years [41], so,
this inconsistency may be related to the short period of cART
administration in our study.The slight decrease in IL-6 levels
can be associated with lower viral load after cART initiation,
to their negative correlation with CD4+ T cell count, also
found in this study, and by the small increase in IL-10 levels.
Besides that, we found a positive correlation between IL-10
with IL-8 and CRP, indicating that probably high IL-10 levels
would be required to cause reduction in other inflammatory
markers.
In the present study, the CRP levels of all patients were
normal or slightly high, considering the reference value at
the two moments studied; however, a significant increase
in its synthesis was observed after treatment. Thus, these
results do not seem to suggest a contribution from cART to
inflammation decrease during the study period. Actually, our
hypothesis is that CRP elevation may be associated with the
increase of parameters related to metabolic syndrome, such
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as triglycerides, which in our study also showed higher values
after therapy. Similar results were found by Masia´ et al. [42]
and Guimara˜es et al. [43] with treated compared to cART-
na¨ıve patients, which demonstrated a positive correlation
between CRP or hs-CRP and triglycerides, lipids, insulin
levels, and systolic and diastolic blood pressure among other
parameters, including Framingham risk score [42, 43]. Nei-
ther viral load nor the CD4+ T counts were correlated with
CRP in these studies; therefore, CRP and hsCRPmay then be
markers for cardiovascular risk linked to HIV infection and
cART [42, 43].
Nevertheless, another study [44] showed that CRP levels
decrease following cART treatment, although they are still
maintained at high levels. However, these authors related
greater levels of CRP to high mortality rates due to car-
diovascular alterations after a short period in malnourished
HIV-infected adults in Africa, the possible explanation of
which was the persistent chronic inflammatory process [44].
Anyway, both levels of CRP as inflammatory cytokines
and metabolic profile are related to the lifestyle of indi-
viduals. Thus, balanced food intake, poor in sodium, fats,
and sugar and with intake of antioxidants, and physical
activity, especially a combination of endurance and strength
training, are important in maintaining or delaying the onset
of lipodystrophy, metabolic syndrome, and other non-AIDS
diseases [45, 46].
The present research investigated other three poorly
studied parameters: AGEs andHMGB1,which are involved in
the induction of cellular activation and trigger inflammatory
responses, and sRAGE, which plays the opposite effect.
After cART initiation, AGEs plasma levels decreased
significantly. Little is known about AGEs concentrations and
their effect on the pathogenesis of HIV infection, especially
in vivo. To our knowledge, this is the first study to evaluate
the effect of cART on the levels of AGEs in asymptomatic
PLWHA. However, different reports suggest that their high
levels are related to the development of various comorbidi-
ties in non-HIV-infected individuals, mainly aging-related
complications, such as cataract formation, atherosclerosis
[11, 47], osteoporosis [13], Alzheimer’s disease [16], chronic
kidney disease, and diabetes mellitus [11, 15]. With regard to
this, cART seems to contribute to improving this parameter.
However, in our study, this improvement was evident only in
patients who began cART with lower CD4+ T counts (<500
cells/mm3), at least after a short-term period of therapy.
Further analyses in long-term cART period are needed to
monitor this key parameter in PLWHA.
Differences in sRAGE levels before and after cART
introduction were not observed in the present study, possibly
because of the short interval analyzed. After all, firstly AGEs
activate the inflammatory cascade with consequent produc-
tion of IL-6, and it is probably only after such induction that
sRAGE increase in the circulation occurs [48]. Hence, after
cART and with the decrease in AGEs levels, there may have
been lower cell stimulation and lower sRAGE production.
Another hypothesis is that, even with a slight, nonsignificant
posttherapy sRAGE increase, there may have been a larger
capture of AGEs by these soluble receptors, thus significantly
reducing their circulating levels in HIV patients after cART.
In the general population, alterations in levels of blood
have been associated with diseases typical of aging, especially
those related to metabolic syndrome [10, 21, 22, 49]. Studies
on sRAGE are scarce in the field of HIV/AIDS despite its
importance for both virus pathogenesis and the management
of chronic diseases in infected individuals. Jeong et al. [21]
found that high concentrations of sRAGE were related to
lower development of atherosclerosis in PLWHA, suggest-
ing a protective role for this marker in one of the major
and most serious comorbidities found in these individuals.
Thus, these authors [21] suggested that the measurement
of plasma sRAGE could be used in clinical practice in an
attempt to predict cardiovascular risk in PLWHA. The same
authors also showed no differences between the cART classes
used, although most patients with high sRAGE were under
NNRTI regimen. Likewise, in the present study, the majority
of patients (83.3%) were receiving a scheme consisting of
NNRTI, which referred to efavirenz. Moreover, we did not
find any relation between the cART classes used by our
patients and the alterations in the studied biomarkers (data
not shown).
High systemic levels of HMGB1 also are found in many
chronic proinflammatory conditions, including diabetesmel-
litus and cancers, as well as in acute conditions, such as
sepsis [17, 32, 50]. An interesting finding is that HMGB1 can
bind and catalyze the movement of LPS monomers from
LPS aggregates thus favoring LPS binding to CD14 which
eventually increase TNF-𝛼 production, via TLR4 activation
[27]. Also, monocyte stimulation with both LPS and HMGB1
results in an increased production of TNF-𝛼 compared to the
case with LPS alone [27].This indicates thatHMGB1may also
induceHIV reactivation in PBMCof individuals under cART
[51]. However, in this study, no differences were observed
in HMGB1 levels before and after cART. In contrast, other
studies have shown increased levels of HMGB1 in PLWHA in
relation to the uninfected population, mainly in patients with
advanced disease [52, 53]. Association between this marker
and the VL of the patients was also observed by Trøseid et al.
[53], in addition to the reduction in both of them after two
years of cART. This was another aspect not observed in this
study, perhaps due to the short period analyzed.
Although the present study has analyzed a small sample
and does not present data on the dietary inquiries of patients,
whichmay also influence the levels of AGEs [54] and of some
metabolic parameters [46], the study population underwent
rigorous exclusion criteria in order to minimize possible
confounding effects in the results, such as the presence of
comorbidities that knowingly induce and are induced by
AGEs, sRAGE, and HMGB1. Another limitation of our study
is related to the time after beginning therapy for the second
analysis, ranging from 6 to 12 months. Shorter measures may
not reflect the steady state level of a given cytokine during
cART, for example, especially in those individuals that still
show detectable VL values. Therefore, although our aim was
to check the marker’s changes in the therapeutic beginning,
the study of these biomarkers in patients on cART for a long
period would also be enlightening. Besides that, the lack of a
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control group can be considered another bias of this study,
due to the lack of parameters measures that are not well
defined in the literature and which could explain some data
founded here.
5. Conclusion
Finally, we concluded that, in the first months of cART, there
was a decrease in glucose pathway oxidation, reducing AGEs
soluble especially in individuals with initial CD4+ T <500
cells/mm3, which would indicate lower immune activation
and an improvement in the inflammatory status of these
patients. However, the analysis of other inflammatory mark-
ers did not show such benefit since the levels of inflammatory
cytokines were notmodified and those of CRP increased over
the same period. Another negative aspect was the increase
in triglycerides in this short period. Because HMGB1 and
sRAGE levels were not modulated by initial therapy, other
pattern-recognition receptors and other products responsible
for cell activation and inflammation could be more informa-
tive in the analyses of chronic inflammation in HIV-infected
individuals.
Therefore, analysis of other markers and further studies
with larger cohorts and in the long term are important to
clarify the influence of drug treatment on the mechanisms of
activation, inflammation, and metabolic changes that affect
the PLWHA. Thence, despite the incontestable benefits of
cART in controllingHIV replication, some strategies could be
useful in preventing/delaying the onset of non-AIDS-defining
illnesses, such as physical exercises practice, a balanced diet,
and other healthy lifestyle habits.
Competing Interests
The authors declare that they have no conflict of interests.
Acknowledgments
Thisworkwas supported by grants from the BrazilianAgency
“CAPES” (Coordenac¸a˜o de Aperfeic¸oamento de Pessoal de
Nı´vel Superior), to Karen Ingrid Tasca, Caio Cavassan de
Camargo; from “Reitoria/UNESP, to Juliana Trindade Caleffi;
and from FAPESP” (Fundac¸a˜o de Amparo a` Pesquisa do
Estado de Sa˜o Paulo) to Mariana Gatto (number 2010/13922-
5). The authors want to acknowledge the efforts of the
personnel from EAP/UNESP, especially Professor Dr. Jose´
Eduardo Corrente for thr help with the statistical analysis.
The authors thank all the people from Tropical Disease
Department, Botucatu Blood Center, Laboratory of Tropical
Diseases and Experimental Research Unit (FMB/UNESP),
especially Professor Dra. Alexandrina Sartori, Professor Dra.
Cilmery S. Kurokawa, Maria Regina Moretto, and Silvia R. T.
Estevan for all help. The authors also thank the patients and
employees of Specialized Outpatient Service of Infectology
“Domingos Alves Meira.”
References
[1] UNAIDS.org. Joint United Nations Programme on HIV/AIDS,
Global AIDS Response Progress Reporting, 2015, http://www
.unaids.org/en/dataanalysis/knowyourresponse/globalaidspro-
gressreporting/.
[2] C. S. Rodrigues, M. D. Guimara˜es, F. A. Acurcio, and C. C.
Comini, “Interrupc¸a˜o do acompanhamento cl´ınico ambulato-
rial de pacientes infectados pelo HIV,” Revista de Sau´de Publica,
vol. 37, no. 2, pp. 183–190, 2003.
[3] A. J. Aberg, “Aging, inflammation, and HIV,” Topics in Antiviral
Medicine, vol. 20, no. 3, pp. 101–105, 2012.
[4] Ministe´rio da Sau´de, Departamento de DST, Aids e Hepatites
Virais, Boletim Epidemiologia Dst Aids, 2014.
[5] G. Guaraldi, G. Orlando, S. Zona et al., “Premature age-related
comorbidities among HIV-infected persons compared with the
general population,” Clinical Infectious Diseases, vol. 53, no. 11,
pp. 1120–1126, 2011.
[6] K. V. Ramana, “Effect of highly active antiretroviral therapy
(HAART) on human immunodeficiency virus disease patho-
genesis and progression,” American Journal of Public Health
Reserch, vol. 2, no. 3, pp. 68–74, 2014.
[7] S. G. Deeks, “HIV infection, inflammation, immuno-
senescence, and aging,” Annual Review of Medicine, vol.
62, pp. 141–155, 2011.
[8] K. Venkataramana, “A study of biological markers in HIV
disease progression and management in the highly active
antiretroviral therapy (HAART) era,” American Journal of Bio-
science and Bioenginnering, vol. 1, no. 2, pp. 24–37, 2013.
[9] T. Hulgan, J. Morrow, R. T. D’Aquila et al., “Oxidant stress is
increased during treatment of human immunodeficiency virus
infection,” Clinical Infectious Diseases, vol. 37, no. 12, pp. 1711–
1717, 2003.
[10] B. I. Hudson, A. M. Holfmann, L. Bucciarelli et al., “Glycation
and diabetes: the RAGE connection,” Current Science, vol. 83,
no. 12, pp. 1515–1521, 2002.
[11] B. K. Kilhovd, T. J. Berg, K. I. Birkeland, P. Thorsby, and K. F.
Hanssen, “Serum levels of advanced glycation end products are
increased in patients with type 2 diabetes and coronary heart
disease,” Diabetes Care, vol. 22, no. 9, pp. 1543–1548, 1999.
[12] B. Knysz, B. Szetela, and A. Gładysz, “Pathogenesis of HIV-1
infection—chosen aspects,” HIV & AIDS Review, vol. 6, no. 1,
pp. 7–11, 2007.
[13] P. Pietschmann, D. Mechtcheriakova, A. Meshcheryakova, U.
Fo¨ger-Samwald, and I. Ellinger, “Immunology of osteoporosis:
a mini-review,” Gerontology, vol. 62, no. 2, pp. 128–137, 2016.
[14] M. Kaneko, L. Bucciarelli, Y. C. Hwang et al., “Aldose reductase
and AGE-RAGE pathways: key players in myocardial ischemic
injury,” Annals of the New York Academy of Sciences, vol. 1043,
pp. 702–709, 2005.
[15] A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E. B.
Reusch, “Diabetes and advanced glycoxidation end products,”
Diabetes Care, vol. 29, no. 6, pp. 1420–1432, 2006.
[16] V. Srikanth, A. Maczurek, T. Phan et al., “Advanced glycation
endproducts and their receptor RAGE in Alzheimer’s disease,”
Neurobiology of Aging, vol. 32, no. 5, pp. 763–777, 2011.
[17] G. P. Sims, D. C. Rowe, S. T. Rietdijk, R. Herbst, and A. J. Coyle,
“HMGB1 and RAGE in inflammation and cancer,” Annual
Review of Immunology, vol. 28, pp. 367–388, 2010.
[18] K. Kierdorf and G. Fritz, “RAGE regulation and signaling in
inflammation and beyond,” Journal of Leukocyte Biology, vol. 94,
no. 1, pp. 55–68, 2013.
8 Mediators of Inflammation
[19] A. Z. Kalea, A. M. Schmidt, and B. I. Hudson, “RAGE: a novel
biological and genetic marker for vascular disease,” Clinical
Science, vol. 116, no. 8, pp. 621–637, 2009.
[20] A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The
multiligand receptor RAGE as a progression factor amplifying
immune and inflammatory responses,” Journal of Clinical Inves-
tigation, vol. 108, no. 7, pp. 949–955, 2001.
[21] S. J. Jeong, C. O. Kim, Y. G. Song et al., “Low plasma levels
of the soluble receptor for advanced glycation end products in
HIV-infected patients with subclinical carotid atherosclerosis
receiving combined antiretroviral therapy,” Atherosclerosis, vol.
219, no. 2, pp. 778–783, 2011.
[22] F. Santilli, L. Bucciarelli, D. Noto et al., “Decreased plasma
soluble RAGE in patients with hypercholesterolemia: effects of
statins,” Free Radical Biology&Medicine, vol. 43, no. 9, pp. 1255–
1262, 2007.
[23] D. Geroldi, C. Falcone, E. Emanuele et al., “Decreased plasma
levels of soluble receptor for advanced glycation end-products
in patients with essential hypertension,” Journal of Hyperten-
sion, vol. 23, no. 9, pp. 1725–1729, 2005.
[24] J. O. Thomas, “HMG 1 and 2: architectural DNA-binding
proteins,” Biochemical Society Transactions, vol. 29, no. 4, pp.
395–401, 2001.
[25] P. Scaffidi, T. Misteli, and M. E. Bianchi, “Release of chro-
matin protein HMGB1 by necrotic cells triggers inflammation,”
Nature, vol. 418, pp. 191–195, 2002.
[26] J. Tian, A. M. Avalos, S.-Y. Mao et al., “Toll-like receptor 9-
dependent activation by DNA-containing immune complexes
is mediated by HMGB1 and RAGE,”Nature Immunology, vol. 8,
no. 5, pp. 487–496, 2007.
[27] J. H. Youn, Y. J. Oh, E. S. Kim, J. E. Choi, and J.-S. Shin,
“High mobility group box 1 protein binding to lipopolysac-
charide facilitates transfer of lipopolysaccharide to CD14 and
enhances lipopolysaccharide-mediated TNF-𝛼 production in
human monocytes,” The Journal of Immunology, vol. 180, no. 7,
pp. 5067–5074, 2008.
[28] V. Urbonaviciute, B. G. Fu¨rnrohr, S. Meister et al., “Induction of
inflammatory and immune responses by HMGB1-nucleosome
complexes: implications for the pathogenesis of SLE,” Journal of
Experimental Medicine, vol. 205, no. 13, pp. 3007–3018, 2008.
[29] M.-L.Gougeon,M.-T.Melki, andH. Saı¨di, “HMGB1, an alarmin
promoting HIV dissemination and latency in dendritic cells,”
Cell Death & Differentiation, vol. 19, no. 1, pp. 96–106, 2012.
[30] U. Andersson and H. E. Harris, “The role of HMGB1 in the
pathogenesis of rheumatic disease,” Biochimica et Biophysica
Acta—Gene Regulatory Mechanisms, vol. 1799, no. 1-2, pp. 141–
148, 2010.
[31] T. Yasuda, T. Ueda, Y. Takeyama et al., “Significant increase of
serum high-mobility group box chromosomal protein 1 levels
in patients with severe acute pancreatitis,” Pancreas, vol. 33, no.
4, pp. 359–363, 2006.
[32] S. Zhang, J. Zhong, P. Yang, F. Gong, and C.-Y.Wang, “HMGB1,
an innate alarmin, in the pathogenesis of type 1 diabetes,”
International Journal of Clinical and Experimental Pathology,
vol. 3, no. 1, pp. 24–38, 2010.
[33] D. V. Havlir, I. C. Marschner, M. S. Hirsch et al., “Maintenance
antiretroviral therapies in HIV-infected subjects with unde-
tectable plasma HIV RNA after triple-drug therapy,” The New
England Journal ofMedicine, vol. 339, no. 18, pp. 1261–1268, 1998.
[34] A. E. C. G. Fukumoto, C. C. Oliveira, K. I. Tasca, and L. D. R.
D. Souza, “Evolution of patients with AIDS after cART: clinical
and laboratory evolution of patients with AIDS after 48 weeks
of antiretroviral treatment,” Revista do Instituto de Medicina
Tropical de Sao Paulo, vol. 55, no. 4, pp. 267–273, 2013.
[35] L. F. D. S. Pinto Neto, M. B. das Neves, R. Ribeiro-Rodrigues,
K. Page, and A. E. Miranda, “Dyslipidemia and fasting glucose
impairment among HIV patients three years after the first
antiretroviral regimen in a Brazilian AIDS outpatient clinic,”
Brazilian Journal of Infectious Diseases, vol. 17, no. 4, pp. 438–
443, 2013.
[36] S. J. Souza, L. A. Luzia, S. Santos, and P.H. C. Rondo´, “Lipid pro-
file ofHIV-infected patients in relation to antiretroviral therapy:
a review,” Revista da Associac¸a˜o Me´dica Brasileira, vol. 59,
no. 2, pp. 186–198, 2013.
[37] J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial
translocation is a cause of systemic immune activation in
chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp.
1365–1371, 2006.
[38] D. C. Hsu, I. Sereti, and J. Ananworanich, “Serious Non-AIDS
events: immunopathogenesis and interventional strategies,”
AIDS Research andTherapy, vol. 10, no. 1, article 29, 2013.
[39] P. W. Hunt, “HIV and inflammation: mechanisms and conse-
quences,” Current HIV/AIDS Reports, vol. 9, no. 2, pp. 139–147,
2012.
[40] J. L. Fahey, “Plasma immune activation markers, and clinically
relevant surrogate markers in human immunodeficiency virus
infection,” Cytokines, vol. 5, no. 5, pp. 597–603, 1998.
[41] S. Hattab, A. Guihot, M. Guiguet et al., “Comparative impact of
antiretroviral drugs on markers of inflammation and immune
activation during the first two years of effective therapy forHIV-
1 infection: An Observational Study,” BMC Infectious Diseases,
vol. 14, no. 1, article 122, 2014.
[42] M. Masia´, E. Bernal, S. Padilla et al., “The role of C-reactive
protein as a marker for cardiovascular risk associated with
antiretroviral therapy in HIV-infected patients,”Atherosclerosis,
vol. 195, no. 1, pp. 167–171, 2007.
[43] M. M. M. Guimara˜es, D. B. Greco, S. M. D. Figueiredo, R. B.
Fo´scolo, A. R. D. Oliveira Jr., and L. J. D. C. Machado, “High-
sensitivity C-reactive protein levels in HIV-infected patients
treated or not with antiretroviral drugs and their correlation
with factors related to cardiovascular risk and HIV infection,”
Atherosclerosis, vol. 201, no. 2, pp. 434–439, 2008.
[44] M. Bestawros, T. Chidumayo, M. Blevins et al., “Increased
systemic inflammation is associated with cardiac and vascular
dysfunction over the first 12 weeks of antiretroviral ther-
apy among undernourished, HIV-infected adults in Southern
Africa,” Journal of AIDS and Clinical Research, vol. 6, no. 3, p.
431, 2015.
[45] B. Lindegaard, T. Hansen, T. Hvid et al., “The effect of strength
and endurance training on insulin sensitivity and fat distri-
bution in human immunodeficiency virus-infected patients
with lipodystrophy,” The Journal of Clinical Endocrinology &
Metabolism, vol. 93, no. 10, pp. 3860–3869, 2008.
[46] L. A. Willig and E. T. Overton, “Metabolic complications and
glucose metabolism in HIV infection: a review of the evidence,”
Current HIV/AIDS Report, vol. 13, pp. 289–296, 2016.
[47] R. D. Semba, E. J. Nicklett, and L. Ferrucci, “Does accumulation
of advanced glycation end products contribute to the aging
phenotype?” Journals of Gerontology—Series A, vol. 65, no. 9,
pp. 963–975, 2010.
[48] A. I. Serban, L. Stanca, O. I. Geicu, and A. Dinischiotu,
“Ages-induced IL-6 synthesis precedes RAGE up-regulation
Mediators of Inflammation 9
in HEK 293 cells: an alternative inflammatory mechanism?”
International Journal of Molecular Sciences, vol. 16, no. 9, pp.
20100–20117, 2015.
[49] B. I. Hudson, C. Dong, H. Gardener et al., “Serum levels of solu-
ble receptor for advanced glycation end-products andmetabolic
syndrome: the Northern Manhattan Study,” Metabolism: Clini-
cal and Experimental, vol. 63, no. 9, pp. 1125–1130, 2014.
[50] H.Wang, O. Bloom,M. Zhang et al., “HMG-1 as a late mediator
of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp.
248–251, 1999.
[51] S.Thierry, J. Gozlan, A. Jaulmes et al., “High-mobility group box
1 protein induces HIV-1 expression from persistently infected
cells,” AIDS, vol. 21, no. 3, pp. 283–292, 2007.
[52] P. Nowak, B. Barqasho, and A. So¨nnerborg, “Elevated plasma
levels of highmobility group box protein 1 in patients withHIV-
1 infection,” AIDS, vol. 21, no. 7, pp. 869–871, 2007.
[53] M. Trøseid, A. So¨nnerborg, and P. Nowak, “High mobility
group box protein-1 in HIV-1 infection: connecting microbial
translocation, cell death and immune activation,” Current HIV
Research, vol. 9, no. 1, pp. 6–10, 2011.
[54] J. Uribarri, M. D. del Castillo, M. P. de la Maza et al., “Dietary
advanced glycation end products and their role in health and
disease,” Advances in Nutrition, vol. 6, no. 4, pp. 461–473, 2015.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
